SUPPLEMENTAL MATERIAL

Table S1. Systolic and Diastolic Blood Pressure*, use of anti-hypertension (anti-HTN) meds and prevalence of HTN (defined as +anti-HTN meds or BP>140/80) from Visit 1 (average age 54), Visit 2 (average age 57), Visit 3 (average age 60), Visit 4 (average age 63) and Visit 5 (average age 76) in blacks and whites.

Characteristic	AA	AG	GG	P-trend
V1 SBP	125.9 ± 0.33	125.6 ± 0.28	124.9 ± 0.45	0.038
V1 DBP	76.1 ± 0.19	75.9 ± 0.16	75.6 ± 0.25	0.074
V1 anti-HTN meds, N (%)	1256 (32.6%)	1697 (31.3%)	589 (29.1%)	
V1 anti-HTN meds, OR (95% CI)	Reference	0.98 (0.89-1.08)	0.92 (0.81-1.04)	0.19
V1 HTN, N (%)	1103 (28.5%)	1536 (28.2%)	542 (26.6%)	
V1 HTN, OR (95% CI)	Reference	0.93 (0.85-1.03)	0.86 (0.76-0.97)	0.012
V2 SBP	126.3 ± 0.34	125.8 ± 0.29	124.7 ± 0.46	0.006
V2 DBP	75.3 ± 0.19	74.9 ± 0.16	74.3 ± 0.26	0.003
V2 anti-HTN meds, N (%)	954 (24.6%)	1303 (23.9%)	441 (21.7%)	
V2 anti-HTN meds, OR (95% CI)	Reference	0.96 (0.87-1.06)	0.85 (0.74-0.97)	0.021
V2 HTN, N (%)	1299 (35.0%)	1766 (33.8%)	595 (30.3%)	
V2 HTN, OR (95% CI)	Reference	0.95 (0.86-1.04)	0.81 (0.72-0.92)	0.002
V3 SBP	129.7± 0.36	128.9± 0.30	128.1 ± 0.49	0.002
V3 DBP	74.5 ± 0.20	74.5 ± 0.17	73.7 ± 0.27	0.036
V3 anti-HTN meds, N (%)	1003 (25.9%)	1354 (24.8%)	478 (23.5%)	
V3 anti-HTN meds, OR (95% CI)	Reference	0.93 (0.85-1.03)	0.85 (0.75-0.98)	0.019
V3 HTN, N (%)	1321 (39.9%)	1790 (38.2%)	644 (36.1%)	
V3 HTN, OR (95% CI)	Reference	0.92 (0.84-1.01)	0.86 (0.76-0.97)	0.010
V4 SBP	133.9 ± 0.38	132.7 ± 0.33	132.5 ± 0.52	0.008
V4 DBP	75.2 ± 0.21	74.6 ± 0.18	74.2 ± 0.28	0.005
V4 anti-HTN meds, N (%)	1083 (28.0%)	1463 (26.8%)	518 (25.5%)	
V4 anti-HTN meds, OR (95% CI)	Reference	0.95 (0.86-1.05)	0.85 (0.75-0.97)	0.020
V4 HTN, N (%)	1444 (47.4%)	1914 (45.2%)	704 (43.4%)	
V4 HTN, OR (95% CI)	Reference	0.90 (0.82-0.99)	0.85 (0.75-0.96)	0.005
V5 SBP	135.8 ± 0.47	133.1± 0.40	134.2 ± 0.62	0.3
V5 DBP	69.3 ± 0.27	68.7 ± 0.23	68.5 ± 0.36	0.059
V5 anti-HTN meds, N (%)	1125 (67.6%)	1519 (65.1%)	626 (67.1%)	

V5 anti-HTN meds, OR (95% CI)	Reference	0.89 (0.78-1.02)	0.99 (0.83-1.18)	0.68
V5 HTN, N (%)	1264 (75.6%)	1694 (72.5%)	692 (73.9%)	
V5 HTN, OR (95% CI)	Reference	0.85 (0.73-0.99)	0.92 (0.77-1.11)	0.2

*Adjusted for age, sex, and race; SBP adjusted for +15mmHg and DBP +10mmHg if patient taking anti-HTN medication. P-values include adjustment for Principle Components.

Table S2. Risk of All cause mortality, Cardiovascular (CV) and non-CV Death based on ICD codes in Subjects in the Atherosclerosis Risk in Communities Study cohort stratified by rs198389 polymorphism in the B-type Natriuretic Peptide gene Post V1 (Model 2 is post V2).

Rs198389	AA	AG	GG	P-value for trend	P-value for recessive model
Total Cohort, N=11,361	3874	5453	2034		
Death, N (%)	1395 (36%)	1958(36%)	678 (33%)		
Death, HR (95% CI), Crude	Reference	1.00 (0.93-1.07)	0.91 (0.83-1.00)	0.069	0.026
Death, HR (95% CI), Age, sex, race	Reference	0.97 (0.90-1.03)	0.90 (0.82-0.99)	0.030	0.049
Death, HR (95% CI), Model 1	Reference	0.97 (0.90-1.04)	0.90 (0.82-1.00)	0.014	0.015
Death, HR (95% CI), Model 2	Reference	0.95 (0.88-1.03)	0.86 (0.78-0.95)	0.005	0.011
CV Death, N (%)	377 (9.7%)	533 (9.8%)	167 (8.2%)		
CV Death, HR (95% CI), Crude	Reference	1.02 (0.88-1.15)	0.84 (0.70-1.00)	0.102	0.031
CV Death, HR (95% CI), Age, sex, race	Reference	0.96 (0.84-1.10)	0.83 (0.69-0.99)	0.059	0.051
CV Death, HR (95% CI), Model 1	Reference	0.97 (0.84-1.11)	0.77 (0.63-0.94)	0.019	0.009
CV Death, HR (95% CI), Model 2	Reference	0.98 (0.84-1.14)	0.75 (0.61-0.92)	0.017	0.005
Non-CV Death, N (%)	797 (20.6%)	1036 (20.4%)	362 (18.8%)		
Non-CV Death, HR (95% CI), Crude	Reference	0.99 (0.90-1.08)	0.90 (0.79-1.01)	0.11	0.066
Non-CV Death, HR (95% CI), Age, sex, race	Reference	0.97 (0.88-1.06)	0.90 (0.79-1.01)	0.088	0.11
Non-CV Death, HR (95% CI), Model 1	Reference	0.97 (0.88-1.06)	0.89 (0.78-1.01)	0.082	0.095
Non-CV Death, HR (95% CI), Model 2	Reference	0.95 (0.85-1.06)	0.84 (0.72-0.97)	0.022	0.032

Model 1= DM, BMI, Tchol, HDL, tobacco use and prior HF; Stratified by age, sex, and race; All models include adjustment for Principle Components

Model 2= Model 1 + genotype-adjusted logNT-proBNP

Figure S1. Risk of Cardiovascular Death in Subjects in the Atherosclerosis Risk in Communities Study cohort with the GG genotype of the rs198389 polymorphism in the B-type Natriuretic Peptide gene versus GA or AA genotypes by study Center.



Adjusted for DM, BMI, Tchol, HDL, tobacco use and prior HF, genotype-adjusted log N-terminal B-type natriuretic peptide, and principle components; Stratified by age, sex, and race.